These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1177 related items for PubMed ID: 26398691

  • 1. INTRAVITREAL AFLIBERCEPT FOR CHOROIDAL NEOVASCULARIZATION DUE TO AGE-RELATED MACULAR DEGENERATION UNRESPONSIVE TO RANIBIZUMAB THERAPY.
    Sarao V, Parravano M, Veritti D, Arias L, Varano M, Lanzetta P.
    Retina; 2016 Apr; 36(4):770-7. PubMed ID: 26398691
    [Abstract] [Full Text] [Related]

  • 2. INCIDENCE AND LONG-TERM VISUAL ACUITY OUTCOMES OF RETINAL PIGMENT EPITHELIUM TEARS AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
    Vazquez-Alfageme C, Nicholson L, Hamilton RD, Patel PJ.
    Retina; 2019 Apr; 39(4):664-669. PubMed ID: 29324593
    [Abstract] [Full Text] [Related]

  • 3. Short-term results of switchback from aflibercept to ranibizumab in neovascular age-related macular degeneration in clinical practice.
    Despreaux R, Cohen SY, Semoun O, Zambrowski O, Jung C, Oubraham H, Souied EH.
    Graefes Arch Clin Exp Ophthalmol; 2016 Apr; 254(4):639-44. PubMed ID: 26092633
    [Abstract] [Full Text] [Related]

  • 4. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.
    Bakall B, Folk JC, Boldt HC, Sohn EH, Stone EM, Russell SR, Mahajan VB.
    Am J Ophthalmol; 2013 Jul; 156(1):15-22.e1. PubMed ID: 23706500
    [Abstract] [Full Text] [Related]

  • 5. Intravitreal aflibercept treatment in eyes with exudative age-related macular degeneration following prior treatment with intravitreal ranibizumab.
    Narayan DS, Muecke J.
    Indian J Ophthalmol; 2015 Nov; 63(11):832-6. PubMed ID: 26669334
    [Abstract] [Full Text] [Related]

  • 6. Intravitreal Aflibercept for Treatment-Resistant Neovascular Age-Related Macular Degeneration: 12-Month Safety and Efficacy Outcomes.
    Chang AA, Broadhead GK, Hong T, Joachim N, Syed A, Schlub TE, Toth L, Peto T, Zhu M.
    Ophthalmic Res; 2015 Nov; 55(2):84-90. PubMed ID: 26637166
    [Abstract] [Full Text] [Related]

  • 7. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration.
    Kumar N, Marsiglia M, Mrejen S, Fung AT, Slakter J, Sorenson J, Freund KB.
    Retina; 2013 Sep; 33(8):1605-12. PubMed ID: 23549101
    [Abstract] [Full Text] [Related]

  • 8. Macular Atrophy in Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial Comparing Ranibizumab and Aflibercept (RIVAL Study).
    Gillies MC, Hunyor AP, Arnold JJ, Guymer RH, Wolf S, Pecheur FL, Munk MR, McAllister IL.
    Ophthalmology; 2020 Feb; 127(2):198-210. PubMed ID: 31619357
    [Abstract] [Full Text] [Related]

  • 9. CONVERSION TO AFLIBERCEPT THERAPY VERSUS CONTINUING WITH RANIBIZUMAB THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION DEPENDENT ON MONTHLY RANIBIZUMAB TREATMENT.
    Mantel I, Gianniou C, Dirani A.
    Retina; 2016 Jan; 36(1):53-8. PubMed ID: 26166797
    [Abstract] [Full Text] [Related]

  • 10. Switching from ranibizumab to aflibercept in choroidal neovascularization secondary to angioid streaks.
    Sekfali R, Mimoun G, Cohen SY, Querques G, Bandello F, Sacconi R, Souied EH, Capuano V.
    Eur J Ophthalmol; 2020 May; 30(3):550-556. PubMed ID: 30880436
    [Abstract] [Full Text] [Related]

  • 11. Worth changing? Clinical effects of switching treatment in neovascular age-related macular degeneration from intravitreal ranibizumab and aflibercept to bevacizumab in a region in southern Sweden.
    Bro T, Hägg S.
    Eur J Ophthalmol; 2021 Jan; 31(1):144-148. PubMed ID: 31642333
    [Abstract] [Full Text] [Related]

  • 12. Intravitreal aflibercept efficacy in neovascular age-related macular degeneration with suboptimal response to anti-vascular endothelial growth factor-A therapy.
    Monés J, Biarnés M, Macbeth Study Group.
    Eur J Ophthalmol; 2020 Sep; 30(5):1082-1090. PubMed ID: 31088111
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Switch to Aflibercept in the Treatment of Neovascular AMD: One-Year Results in Clinical Practice.
    Pinheiro-Costa J, Costa JM, Beato JN, Freitas-da-Costa P, Brandão E, Falcão MS, Falcão-Reis F, Carneiro ÂM.
    Ophthalmologica; 2015 Sep; 233(3-4):155-61. PubMed ID: 25896317
    [Abstract] [Full Text] [Related]

  • 17. PIGMENT EPITHELIAL DETACHMENT RESPONSE TO AFLIBERCEPT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION REFRACTORY TO RANIBIZUMAB: Time Course and Drug Effects.
    de Massougnes S, Dirani A, Ambresin A, Decugis D, Marchionno L, Mantel I.
    Retina; 2016 May; 36(5):881-8. PubMed ID: 27115852
    [Abstract] [Full Text] [Related]

  • 18. Differential Response to Anti-VEGF Regimens in Age-Related Macular Degeneration Patients with Early Persistent Retinal Fluid.
    Jaffe GJ, Kaiser PK, Thompson D, Gibson A, Saroj N, Vitti R, Berliner AJ, Heier JS.
    Ophthalmology; 2016 Sep; 123(9):1856-64. PubMed ID: 27369111
    [Abstract] [Full Text] [Related]

  • 19. Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors.
    Ho VY, Yeh S, Olsen TW, Bergstrom CS, Yan J, Cribbs BE, Hubbard GB.
    Am J Ophthalmol; 2013 Jul; 156(1):23-28.e2. PubMed ID: 23664153
    [Abstract] [Full Text] [Related]

  • 20. Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data from an Observational Study.
    Gillies MC, Nguyen V, Daien V, Arnold JJ, Morlet N, Barthelmes D.
    Ophthalmology; 2016 Dec; 123(12):2545-2553. PubMed ID: 27707549
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 59.